Article Text

Download PDFPDF
BMJ Rapid Recommendations on use of proprotein convertase subtilisin/kexin 9 inhibitors and ezetimibe to reduce cardiovascular risk

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Correction notice This article has been corrected since it was first published online. The title and DOI were incorrect for reference 4, and it has now been amended.

  • Contributors HDW is responsible for planning, conduct and reporting of the work described in the article.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests HDW has received grant support paid to the institution and fees for serving on the steering committees of the ODYSSEY trial from Sanofi and Regeneron Pharmaceuticals, the ISCHEMIA and the MINT studies from the National Institutes of Health, the STRENGTH trial from Omthera Pharmaceuticals, the HEART-FID study from American Regent, the DAL-GENE study from DalCor Pharma UK, the AEGIS-II study from CSL Behring, the SCORED and SOLOIST-WHF from Sanofi Aventis Australia, and the CLEAR OUTCOMES study from Esperion Therapeutics. HDW is a member of the Cholesterol Treatment Trialists’ Collaboration.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles